Key result
Two-month dual antiplatelet therapy after OPTIMA tacrolimus-eluting stent implantation was associated with a lower 12-month MACE rate compared to 6-month therapy (3.2% vs 6.8%, p=0.001).
Why the study?
Does a 2-month dual antiplatelet therapy strategy compared to a 6-month strategy improve outcomes in patients receiving an OPTIMA tacrolimus-eluting stent?
Cohort (n=106)
Open-label
Non-randomized
No
Does a 2-month dual antiplatelet therapy strategy compared to a 6-month strategy improve outcomes in patients receiving an OPTIMA tacrolimus-eluting stent?
A 2-month dual antiplatelet therapy strategy after OPTIMA tacrolimus-eluting stent implantation appears safe and is associated with low MACE rates at 12 months, though baseline differences in lesion complexity limit direct comparison with the 6-month strategy.
May support shorter DAPT after OPTIMA stent; leaves open randomized confirmation given observational design and baseline imbalances.
INTRODUCTION: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. METHODS: In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events (MACE), stent thrombosis rate and target lesion revascularization (TLR) were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. RESULTS: No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group (6.8% vs. 3.2% respectively, P=0.001) which may be due to this group having more diffuse disease (23.60±5.69 vs. 20.88±5.14, P=0.018). CONCLUSION: OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Aslanabadi et al. (2012) conducted a cohort in Coronary artery disease (n=106). 2-month dual antiplatelet therapy vs. 6-month dual antiplatelet therapy was evaluated on Major Adverse Cardiac Events (MACE) at 12 months (p=0.001). Two-month dual antiplatelet therapy after OPTIMA tacrolimus-eluting stent implantation was associated with a lower 12-month MACE rate compared to 6-month therapy (3.2% vs 6.8%, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: